What is Strata Skin Sciences Inc's earnings per share (EPS)?

Strata Skin Sciences Inc (SSKN) reported diluted earnings per share of $-1.35 for fiscal year 2025. This represents a 49.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Strata Skin Sciences Inc Financials

SSKN

Source SEC Filings (10-K/10-Q) Updated Mar 25, 2026 Currency USD FYE March

This page shows Strata Skin Sciences Inc (SSKN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 4/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Strata Skin Sciences Inc has an operating margin of -15.3%, meaning the company retains $-15 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -27.6% the prior year.

Growth

Strata Skin Sciences Inc's revenue declined 8.5% year-over-year, from $33.6M to $30.7M. This contraction results in a growth score of 19/100.

Leverage

Strata Skin Sciences Inc has elevated debt relative to equity (D/E of 5.22), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Strata Skin Sciences Inc's current ratio of 0.58 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 6/100, which could limit financial flexibility.

Cash Flow

While Strata Skin Sciences Inc generated -$2.8M in operating cash flow, capex of $1.5M consumed most of it, leaving -$4.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Strata Skin Sciences Inc generates a -215.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -202.9% the prior year.

Piotroski F-Score Neutral

4/9

Strata Skin Sciences Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.45x

For every $1 of reported earnings, Strata Skin Sciences Inc generates $0.45 in operating cash flow (-$2.8M OCF vs -$6.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-2.4x

Strata Skin Sciences Inc earns $-2.4 in operating income for every $1 of interest expense (-$4.7M vs $2.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$30.7M

YoY-8.5%

5Y CAGR+5.9%

10Y CAGR+5.2%

Strata Skin Sciences Inc generated $30.7M in revenue in fiscal year 2025. This represents a decrease of 8.5% from the prior year.

EBITDA

-$883K

YoY+79.4%

Strata Skin Sciences Inc's EBITDA was -$883K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 79.4% from the prior year.

Net Income

-$6.3M

YoY+37.9%

Strata Skin Sciences Inc reported -$6.3M in net income in fiscal year 2025. This represents an increase of 37.9% from the prior year.

EPS (Diluted)

$-1.35

YoY+49.1%

Strata Skin Sciences Inc earned $-1.35 per diluted share (EPS) in fiscal year 2025. This represents an increase of 49.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$4.3M

YoY-194.3%

Strata Skin Sciences Inc generated -$4.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 194.3% from the prior year.

Cash & Debt

$7.9M

YoY+9.0%

5Y CAGR-5.7%

10Y CAGR+9.1%

Strata Skin Sciences Inc held $7.9M in cash against $15.2M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+41.2%

Strata Skin Sciences Inc had 6M shares outstanding in fiscal year 2025. This represents an increase of 41.2% from the prior year.

Margins & Returns

Gross Margin

58.3%

YoY+1.4pp

5Y CAGR-3.0pp

10Y CAGR+32.4pp

Strata Skin Sciences Inc's gross margin was 58.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the prior year.

Operating Margin

-15.3%

YoY+12.3pp

5Y CAGR+2.3pp

10Y CAGR+73.8pp

Strata Skin Sciences Inc's operating margin was -15.3% in fiscal year 2025, reflecting core business profitability. This is up 12.3 percentage points from the prior year.

Net Margin

-20.4%

YoY+9.7pp

5Y CAGR-1.3pp

10Y CAGR+114.5pp

Strata Skin Sciences Inc's net profit margin was -20.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 9.7 percentage points from the prior year.

Return on Equity

-215.3%

YoY-12.4pp

5Y CAGR-198.3pp

10Y CAGR-60.2pp

Strata Skin Sciences Inc's ROE was -215.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 12.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$421K

YoY-52.3%

5Y CAGR-19.9%

10Y CAGR-14.6%

Strata Skin Sciences Inc invested $421K in research and development in fiscal year 2025. This represents a decrease of 52.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.5M

YoY-10.3%

5Y CAGR-7.4%

Strata Skin Sciences Inc invested $1.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 10.3% from the prior year.

SSKN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$30.7M-8.5%	$33.6M+0.6%	$33.4M-7.8%	$36.2M+20.6%	$30.0M+29.8%	$23.1M
Cost of Revenue	$12.8M-11.5%	$14.5M-2.8%	$14.9M+3.5%	$14.4M+42.1%	$10.1M+13.1%	$9.0M
Gross Profit	$17.9M-6.3%	$19.1M+3.4%	$18.5M-15.2%	$21.8M+9.7%	$19.9M+40.4%	$14.1M
R&D Expenses	$421K-52.3%	$883K-33.0%	$1.3M+28.0%	$1.0M-28.2%	$1.4M+12.6%	$1.3M
SG&A Expenses	$10.2M-6.5%	$10.9M+3.7%	$10.5M+4.2%	$10.1M+3.9%	$9.7M+23.0%	$7.9M
Operating Income	-$4.7M+49.2%	-$9.3M-7.6%	-$8.6M-85.1%	-$4.6M-5.6%	-$4.4M-8.0%	-$4.1M
Interest Expense	$2.0M-5.1%	$2.1M+28.5%	$1.6M+77.1%	$926K+194.9%	$314K+48.8%	$211K
Income Tax	$12K+107.1%	-$170K-84.8%	-$92K-246.0%	$63K+85.3%	$34K-87.6%	$275K
Net Income	-$6.3M+37.9%	-$10.1M+6.9%	-$10.8M-95.2%	-$5.5M-105.1%	-$2.7M+38.7%	-$4.4M
EPS (Diluted)	$-1.35+49.1%	$-2.65+14.5%	$-3.10	$-0.16	N/A	$-0.13

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$6.9M-9.6%	$7.7M+12.5%	$6.8M-28.9%	$9.6M+8.9%	$8.8M+4.3%	$8.4M+24.9%	$6.8M-22.3%	$8.7M
Cost of Revenue	$2.7M-18.2%	$3.4M+6.1%	$3.2M-17.5%	$3.8M+9.3%	$3.5M+1.5%	$3.5M-5.9%	$3.7M-5.5%	$3.9M
Gross Profit	$4.2M-2.8%	$4.3M+18.1%	$3.6M-36.4%	$5.7M+8.6%	$5.3M+6.2%	$5.0M+61.6%	$3.1M-35.8%	$4.8M
R&D Expenses	$172K+100.0%	$86K-10.4%	$96K-52.0%	$200K-17.7%	$243K+22.1%	$199K-17.4%	$241K-36.6%	$380K
SG&A Expenses	$2.7M-11.0%	$3.0M+32.4%	$2.3M-4.3%	$2.4M-34.7%	$3.6M+64.4%	$2.2M-18.7%	$2.7M-3.9%	$2.8M
Operating Income	-$1.2M+49.2%	-$2.3M-35.5%	-$1.7M+60.2%	-$4.3M-167.0%	-$1.6M-235.8%	-$478K+83.4%	-$2.9M+16.1%	-$3.4M
Interest Expense	$498K+1.4%	$491K+1.0%	$486K-5.6%	$515K-4.1%	$537K+1.1%	$531K+1.3%	$524K-0.8%	$528K
Income Tax	$0	$0	$0+100.0%	-$170K	$0	$0	$0+100.0%	-$92K
Net Income	-$1.6M+37.0%	-$2.6M-21.3%	-$2.1M+53.4%	-$4.6M-119.6%	-$2.1M-2179.1%	-$91K+97.3%	-$3.4M+11.3%	-$3.8M
EPS (Diluted)	$-0.36+41.9%	$-0.62-21.6%	$-0.51	N/A	$-0.51-1600.0%	$-0.03	$-0.10	N/A

SSKN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$30.5M-12.6%	$34.9M-16.9%	$42.0M-19.6%	$52.3M+12.2%	$46.6M-0.4%	$46.8M
Current Assets	$15.6M-6.0%	$16.6M+6.8%	$15.5M+3.3%	$15.1M-24.6%	$20.0M-19.6%	$24.8M
Cash & Equivalents	$7.9M+9.0%	$7.3M+7.0%	$6.8M+24.8%	$5.4M-56.8%	$12.6M+18.7%	$10.6M
Inventory	$2.8M+25.3%	$2.2M-16.0%	$2.7M-13.6%	$3.1M-11.3%	$3.5M+1.3%	$3.4M
Accounts Receivable	$4.1M-21.5%	$5.3M+18.3%	$4.4M-0.7%	$4.5M+30.2%	$3.4M+16.6%	$2.9M
Goodwill	$1.4M0.0%	$1.4M-78.1%	$6.5M-25.9%	$8.8M0.0%	$8.8M0.0%	$8.8M
Total Liabilities	$27.6M-7.8%	$30.0M+2.1%	$29.3M-3.7%	$30.4M+43.7%	$21.2M+1.4%	$20.9M
Current Liabilities	$26.7M+99.6%	$13.4M+10.0%	$12.2M-9.3%	$13.4M+4.9%	$12.8M-32.0%	$18.8M
Long-Term Debt	$15.2M0.0%	$15.2M+1.0%	$15.0M+101.2%	$7.5M+2.1%	$7.3M+597.0%	$1.1M
Total Equity	$2.9M-41.5%	$5.0M-60.8%	$12.7M-41.9%	$21.8M-14.1%	$25.4M-1.8%	$25.9M
Retained Earnings	-$254.4M-2.5%	-$248.1M-4.2%	-$238.1M-4.8%	-$227.2M-2.5%	-$221.7M-1.2%	-$219.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$30.7M+4.2%	$29.5M-10.7%	$33.0M-5.4%	$34.9M-11.3%	$39.4M+1.6%	$38.8M-1.2%	$39.2M-6.6%	$42.0M
Current Assets	$14.3M+3.6%	$13.8M-13.2%	$15.9M-4.3%	$16.6M+4.5%	$15.9M+14.9%	$13.8M+4.4%	$13.2M-14.8%	$15.5M
Cash & Equivalents	$7.1M+18.6%	$6.0M-8.4%	$6.5M-10.3%	$7.3M+2.8%	$7.1M+28.8%	$5.5M+4.7%	$5.2M-22.8%	$6.8M
Inventory	$3.1M-5.5%	$3.2M+21.7%	$2.7M+18.4%	$2.2M-18.1%	$2.7M+1.9%	$2.7M-0.1%	$2.7M+0.8%	$2.7M
Accounts Receivable	$3.5M-12.9%	$4.0M-19.7%	$5.0M-4.7%	$5.3M+18.2%	$4.4M+11.7%	$4.0M+9.6%	$3.6M-18.2%	$4.4M
Goodwill	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M-74.9%	$5.7M0.0%	$5.7M0.0%	$5.7M-12.6%	$6.5M
Total Liabilities	$29.4M+1.5%	$29.0M-3.6%	$30.1M+0.3%	$30.0M-0.1%	$30.0M+2.5%	$29.3M-1.8%	$29.8M+1.6%	$29.3M
Current Liabilities	$15.0M+19.8%	$12.6M-7.7%	$13.6M+1.5%	$13.4M+1.8%	$13.2M+16.5%	$11.3M-3.9%	$11.8M-3.4%	$12.2M
Long-Term Debt	$13.4M-12.0%	$15.3M+0.3%	$15.2M+0.3%	$15.2M+0.3%	$15.2M+0.3%	$15.1M+0.3%	$15.1M+0.2%	$15.0M
Total Equity	$1.3M+147.0%	$532K-82.1%	$3.0M-40.1%	$5.0M-47.1%	$9.4M-1.1%	$9.5M+0.8%	$9.4M-25.6%	$12.7M
Retained Earnings	-$254.5M-0.6%	-$252.8M-1.0%	-$250.3M-0.9%	-$248.1M-1.9%	-$243.6M-0.9%	-$241.5M0.0%	-$241.4M-1.4%	-$238.1M

SSKN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$2.8M-1586.2%	$188K+136.2%	-$519K+43.8%	-$924K-161.3%	$1.5M-28.1%	$2.1M
Capital Expenditures	$1.5M-10.3%	$1.6M-67.4%	$5.0M+34.3%	$3.7M+2.3%	$3.7M+69.2%	$2.2M
Free Cash Flow	-$4.3M-194.3%	-$1.4M+73.9%	-$5.5M-18.8%	-$4.7M-117.2%	-$2.1M-3304.8%	-$63K
Investing Cash Flow	-$1.5M+10.3%	-$1.6M+67.4%	-$5.0M-14.9%	-$4.4M+38.7%	-$7.1M-230.1%	-$2.2M
Financing Cash Flow	$3.6M+85.9%	$1.9M-71.9%	$6.9M+1472.2%	-$500K-643.5%	$92K-96.4%	$2.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$64K+96.7%	-$1.9M-252.9%	-$550K-178.2%	$703K+332.8%	-$302K-151.1%	$591K+173.5%	-$804K-158.6%	$1.4M
Capital Expenditures	$1.0M+1768.9%	-$61K-130.7%	$199K-60.5%	$504K+712.9%	$62K-82.0%	$345K-52.4%	$725K-57.8%	$1.7M
Free Cash Flow	-$1.1M+46.0%	-$2.0M-167.3%	-$749K-476.4%	$199K+154.7%	-$364K-248.0%	$246K+116.1%	-$1.5M-340.6%	-$347K
Investing Cash Flow	-$1.0M-1768.9%	$61K+130.7%	-$199K+60.5%	-$504K-712.9%	-$62K+82.0%	-$345K+52.4%	-$725K+57.8%	-$1.7M
Financing Cash Flow	$2.2M	$0	$0	$0-100.0%	$1.9M	$0+100.0%	-$18K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SSKN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	58.3%+1.4pp	56.9%+1.5pp	55.3%-4.9pp	60.2%-6.0pp	66.2%+5.0pp	61.2%
Operating Margin	-15.3%+12.3pp	-27.6%-1.8pp	-25.8%-12.9pp	-12.9%+1.8pp	-14.7%+3.0pp	-17.6%
Net Margin	-20.4%+9.7pp	-30.0%+2.4pp	-32.5%-17.1pp	-15.3%-6.3pp	-9.0%+10.1pp	-19.1%
Return on Equity	-215.3%-12.4pp	-202.9%-117.5pp	-85.4%-59.9pp	-25.4%-14.8pp	-10.7%+6.4pp	-17.0%
Return on Assets	-20.5%+8.4pp	-28.9%-3.1pp	-25.8%-15.2pp	-10.6%-4.8pp	-5.8%+3.6pp	-9.4%
Current Ratio	0.58-0.7	1.24-0.0	1.28+0.2	1.12-0.4	1.56+0.2	1.32
Debt-to-Equity	5.22+2.2	3.06+1.9	1.19+0.8	0.34+0.1	0.29+0.2	0.04
FCF Margin	-13.9%-9.6pp	-4.3%+12.3pp	-16.6%-3.7pp	-12.9%-5.7pp	-7.2%-6.9pp	-0.3%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	60.4%+4.2pp	56.2%+2.6pp	53.5%-6.4pp	59.9%-0.2pp	60.1%+1.1pp	59.0%+13.4pp	45.6%-9.6pp	55.3%
Operating Margin	-16.9%+13.2pp	-30.1%-5.1pp	-25.0%+19.7pp	-44.8%-26.5pp	-18.2%-12.6pp	-5.7%+37.1pp	-42.8%-3.1pp	-39.6%
Net Margin	-23.4%+10.2pp	-33.6%-2.5pp	-31.1%+16.4pp	-47.6%-24.0pp	-23.6%-22.5pp	-1.1%+48.8pp	-49.8%-6.2pp	-43.7%
Return on Equity	-123.4%+360.6pp	-484.0%-412.8pp	-71.2%+20.4pp	-91.6%-69.5pp	-22.1%-21.1pp	-1.0%+34.7pp	-35.7%-5.8pp	-29.9%
Return on Assets	-5.3%+3.5pp	-8.7%-2.3pp	-6.4%+6.6pp	-13.0%-7.8pp	-5.3%-5.0pp	-0.2%+8.3pp	-8.6%+0.5pp	-9.0%
Current Ratio	0.95-0.1	1.10-0.1	1.17-0.1	1.24+0.0	1.21-0.0	1.22+0.1	1.13-0.2	1.28
Debt-to-Equity	10.22-18.5	28.70+23.6	5.11+2.1	3.06+1.4	1.61+0.0	1.590.0	1.60+0.4	1.19
FCF Margin	-15.6%+10.5pp	-26.1%-15.1pp	-11.0%-13.1pp	2.1%+6.2pp	-4.1%-7.1pp	2.9%+25.6pp	-22.6%-18.6pp	-4.0%

Note: The current ratio is below 1.0 (0.58), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

HeartSciences Inc HSCS

$7.5M

Biomerica Inc BMRA

$6.6M

Pavmed PAVM

$14.6M

ReShape Lifesciences Inc. RSLS

$7.6M

Lifeward Ltd LFWD

$25.7M

Frequently Asked Questions

What is Strata Skin Sciences Inc's annual revenue?

Strata Skin Sciences Inc (SSKN) reported $30.7M in total revenue for fiscal year 2025. This represents a -8.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Strata Skin Sciences Inc's revenue growing?

Strata Skin Sciences Inc (SSKN) revenue declined by 8.5% year-over-year, from $33.6M to $30.7M in fiscal year 2025.

Is Strata Skin Sciences Inc profitable?

No, Strata Skin Sciences Inc (SSKN) reported a net income of -$6.3M in fiscal year 2025, with a net profit margin of -20.4%.

What is Strata Skin Sciences Inc's EBITDA?

Strata Skin Sciences Inc (SSKN) had EBITDA of -$883K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Strata Skin Sciences Inc have?

As of fiscal year 2025, Strata Skin Sciences Inc (SSKN) had $7.9M in cash and equivalents against $15.2M in long-term debt.

What is Strata Skin Sciences Inc's gross margin?

Strata Skin Sciences Inc (SSKN) had a gross margin of 58.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Strata Skin Sciences Inc's operating margin?

Strata Skin Sciences Inc (SSKN) had an operating margin of -15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Strata Skin Sciences Inc's net profit margin?

Strata Skin Sciences Inc (SSKN) had a net profit margin of -20.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Strata Skin Sciences Inc's return on equity (ROE)?

Strata Skin Sciences Inc (SSKN) has a return on equity of -215.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Strata Skin Sciences Inc's free cash flow?

Strata Skin Sciences Inc (SSKN) generated -$4.3M in free cash flow during fiscal year 2025. This represents a -194.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Strata Skin Sciences Inc's operating cash flow?

Strata Skin Sciences Inc (SSKN) generated -$2.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Strata Skin Sciences Inc's total assets?

Strata Skin Sciences Inc (SSKN) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Strata Skin Sciences Inc's capital expenditures?

Strata Skin Sciences Inc (SSKN) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Strata Skin Sciences Inc spend on research and development?

Strata Skin Sciences Inc (SSKN) invested $421K in research and development during fiscal year 2025.

How many shares does Strata Skin Sciences Inc have outstanding?

Strata Skin Sciences Inc (SSKN) had 6M shares outstanding as of fiscal year 2025.

What is Strata Skin Sciences Inc's current ratio?

Strata Skin Sciences Inc (SSKN) had a current ratio of 0.58 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Strata Skin Sciences Inc's debt-to-equity ratio?

Strata Skin Sciences Inc (SSKN) had a debt-to-equity ratio of 5.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Strata Skin Sciences Inc's return on assets (ROA)?

Strata Skin Sciences Inc (SSKN) had a return on assets of -20.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Strata Skin Sciences Inc's cash runway?

Based on fiscal year 2025 data, Strata Skin Sciences Inc (SSKN) had $7.9M in cash against an annual operating cash burn of $2.8M. This gives an estimated cash runway of approximately 34 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Strata Skin Sciences Inc's Piotroski F-Score?

Strata Skin Sciences Inc (SSKN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Strata Skin Sciences Inc's earnings high quality?

Strata Skin Sciences Inc (SSKN) has an earnings quality ratio of 0.45x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Strata Skin Sciences Inc cover its interest payments?

Strata Skin Sciences Inc (SSKN) has an interest coverage ratio of -2.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Strata Skin Sciences Inc?

Strata Skin Sciences Inc (SSKN) scores 4 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.